Tenatoprazole

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]:22

Tenatoprazole
Clinical data
Routes of
administration		Oral
ATC code
  • none
Pharmacokinetic data
MetabolismHepatic (CYP2C19-mediated)
Elimination half-life4.8 to 7.7 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.120.697
Chemical and physical data
FormulaC16H18N4O3S
Molar mass346.405 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  (verify)

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]:27 and again in 2012.[3]:17

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]

See also

References
  1. "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
  2. "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011.
  3. "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012.
  4. "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.
  5. Li H, Meng L, Liu F, Wei JF, Wang YQ (January 2013). "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents. 23 (1): 99–111. doi:10.1517/13543776.2013.741121. PMID 23205582.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.